全文获取类型
收费全文 | 541386篇 |
免费 | 39802篇 |
国内免费 | 13815篇 |
学科分类
医药卫生 | 595003篇 |
出版年
2023年 | 2970篇 |
2022年 | 7131篇 |
2021年 | 10288篇 |
2020年 | 7829篇 |
2019年 | 7338篇 |
2018年 | 9564篇 |
2017年 | 8581篇 |
2016年 | 8380篇 |
2015年 | 11738篇 |
2014年 | 15108篇 |
2013年 | 17198篇 |
2012年 | 24201篇 |
2011年 | 25421篇 |
2010年 | 17716篇 |
2009年 | 15469篇 |
2008年 | 20224篇 |
2007年 | 20581篇 |
2006年 | 19870篇 |
2005年 | 17449篇 |
2004年 | 14555篇 |
2003年 | 13957篇 |
2002年 | 12662篇 |
2001年 | 31531篇 |
2000年 | 31297篇 |
1999年 | 25571篇 |
1998年 | 6284篇 |
1997年 | 5316篇 |
1996年 | 4677篇 |
1995年 | 4250篇 |
1994年 | 3696篇 |
1993年 | 3211篇 |
1992年 | 16410篇 |
1991年 | 15087篇 |
1990年 | 14407篇 |
1989年 | 14156篇 |
1988年 | 12743篇 |
1987年 | 12212篇 |
1986年 | 11216篇 |
1985年 | 10406篇 |
1984年 | 6957篇 |
1983年 | 5631篇 |
1982年 | 2745篇 |
1979年 | 5509篇 |
1978年 | 3361篇 |
1977年 | 2990篇 |
1975年 | 2653篇 |
1974年 | 3085篇 |
1973年 | 2892篇 |
1972年 | 2834篇 |
1971年 | 2780篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的:对应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果进行研究。方法整群选择在该院2012年12月—2014年12月就诊的患有脑血栓疾病的患者86例,随机分为对照组和治疗组,每组43例。采用奥扎格雷对对照组患者实施治疗;采用低分子肝素钙与奥扎格雷联合对治疗组患者实施治疗。对比神经功能缺损评分在药物治疗前后的变化幅度、脑神经功能恢复正常时间和脑血栓药物治疗计划实施总时间、脑血栓疾病药物治疗效果、用药期间的不良反应人数。结果治疗组患者神经功能缺损评分在药物治疗前后的变化幅度明显大于对照组;脑神经功能恢复正常时间(9.66±2.41)d和脑血栓药物治疗计划实施总时间(13.28±2.14)d明显短于对照组(13.62±3.47)、(17.39±3.20)d;脑血栓疾病药物治疗效果(总有效率90.6%)明显优于对照组(总有效率69.8%);用药期间的不良反应人数(1例)明显少于对照组(8例)。结论应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果非常明显。 相似文献
3.
4.
5.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs. 相似文献
6.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
7.
8.
9.
10.